Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

The Experimental Pharmacotherapy of Benzodiazepine Withdrawal

Author(s): J. Podhorna

Volume 8 , Issue 1 , 2002

Page: [23 - 43] Pages: 21

DOI: 10.2174/1381612023396636

Price: $65

Abstract

In many people, long-term benzodiazepine (BZ) use produces dependence with manifestation of withdrawal symptoms after abrupt cessation of BZ treatment. The current therapy of BZ dependence in humans utilizes gradual dose-taper to avoid withdrawal symptoms and supportive psychotherapy to help patients cope with withdrawal reactions. The failure of dose-taper in many patients has triggered intensive animal research to find additional pharmacological treatments. The present article reviews evidence from animal studies on effectiveness of pharmacological treatment for BZ dependence and withdrawal. It explores the risk-benefit profiles of putative therapies for BZ withdrawal, including drugs acting via benzodiazepine receptors, serotonergic and noradrenergic agents, cholecystokinin-B receptor antagonists, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, and other miscellaneous agents.

Keywords: Benzodiazepine Withdrawal, Cholecystokinin-B (CCK-B), Baclofen, Benzodiazepine


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy